Short term tapering of Ruxolitinib prior conditioning therapy with allogeneic stem cell transplantation for primary myelofibrosis

Short term tapering of Ruxolitinib prior conditioning therapy with allogeneic stem cell transplantation for primary myelofibrosis - Short term tapering of Ruxolitinib prior allo-SCT for primary MF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019421

Enrollment

Registered

2015-10-20

Start date

2015-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary myelofibrosis

Interventions

6 days taparing off of Ruxolitinib prior conditioning therapy with allogeneic stem cell transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.More than Intermediate-2 (DIPSS plus) of primary myelofibrosis 2.HLA-A,-B,-DR antigen fullmatch or 1 locus mismatch related or unrelated donor 3.0 to 2 of ECOG performance status 4.More than 40% of Ejection Fraction in cardiac ultrasonography 5.More than 94% of SpO2 in room air 6.More than 70% of vital capacity and more than 70% of FEV1/FVC 7..Less than 2.0mg/dl of serum bilirubin and less than 5-fold ULN of AST 8.More than 40ml/min of eGFR

Exclusion criteria

Exclusion criteria: 1.Positive of HBs antigen, HCV antibody, HIV antibody or HTLV-1 antibody 2.Uncontrollable psychiatric symptom 3.Pregnant woman or lactating 4.Active other cancers 5.Uncontrollable active infection 6.Hepatic cirrhosis 7.More than BMI 35 8.Others

Design outcomes

Primary

Measure	Time frame
1.Engraftment and survival at 4 weeks after allo-SCT 2.Analysis of cytokine and growth factor during Allo-SCt	—

Secondary

Measure	Time frame
1.Survival at 12 weeks after allo-SCT 2.Disease status at 4 and 12 weeks after Allo-SCT 3.Acute GVHD 4.Infection 5.Adverse event (CTCAE ver.4 Grade3 or more) 6.Analysis of lymphocyte subsets and immunoglobulin at 4, 8 and 12 weeks after allo-SCT	—

Countries

Japan

Contacts

Public ContactShiratori Souichi

Hokkaido University Hospital, Sapporo, Hokkaido, Japan Department of Hematology

s.shiratori@med.hokudai.ac.jp011-706-7214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026